GGrantIndex
← Leaderboards

Sang Ging Ong

Stanford University

$4,302,589
Attributed
$4,302,589
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $841.1K · FY201625
$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,302,589 · 4

By mechanism

R01$3,117,081 · 2
R00$927,121 · 1
K99$258,387 · 1

Top collaborators

No co-investigators on record.

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsResponseCardiac MyocytesInduced Pluripotent Stem CellDiabetes MellitusPredispositionCardiacDiabetic PatientDiabetic CardiomyopathyPathogenesisPreventPathway InteractionsStressMitochondriaCause Of DeathMolecularHyperglycemiaImpairmentCardiovascular DiseasesHeartDiabeticGeneticBaseAutophagocytosis

Grant awards (13)

Molecular mechanisms of translational control in sunitinib-induced vascular dysfunction$701,890
R01 · FY2025 · HL · contact PI
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy$411,962
R01 · FY2024 · HL · contact PI
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy$411,962
R01 · FY2023 · HL · contact PI
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy$411,962
R01 · FY2022 · HL · contact PI
Dysfunctional Endosomal-Mediated Mitochondrial Clearance Linking Vascular Dysfunction to Alzheimer's Disease: Administrative Supplement for HL148756$355,381
R01 · FY2022 · HL · contact PI
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy$411,962
R01 · FY2021 · HL · contact PI
Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathy$411,962
R01 · FY2020 · HL · contact PI
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through Mitophagy$248,999
R00 · FY2020 · HL · contact PI
CARDIAC MITOHORMESIS PROTECTS AGAINST DIABETIC CARDIOMYOPATHY THROUGH MITOPHAGY: EVALI ADMINISTRATIVE SUPPLEMENT$180,124
R00 · FY2020 · HL · contact PI
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through Mitophagy$248,999
R00 · FY2019 · HL · contact PI
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through Mitophagy$248,999
R00 · FY2018 · HL · contact PI
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through Mitophagy$130,704
K99 · FY2017 · HL · contact PI
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through Mitophagy$127,683
K99 · FY2016 · HL · contact PI